Structural and molecular cholinergic imaging markers of cognitive decline in Parkinson's disease

被引:15
作者
Schumacher, Julia [1 ,2 ,12 ]
Kanel, Prabesh [3 ,4 ,5 ]
Dyrba, Martin [1 ]
Storch, Alexander [1 ,2 ]
Bohnen, Nicolaas, I [3 ,4 ,5 ,6 ,7 ,8 ]
Teipel, Stefan [1 ,9 ]
Grothe, Michel J. [10 ,11 ,13 ]
机构
[1] Deutsch Zentrum Neurodegenerat Erkrankungen DZNE R, D-18147 Rostock, Germany
[2] Univ Med Ctr Rostock, Dept Neurol, D-18147 Rostock, Germany
[3] Univ Michigan, Morris K Udall Ctr Excellence Parkinsons Dis Res, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Parkinsons Fdn Res Ctr Excellence, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Dept Radiol, Ann Arbor, MI 48105 USA
[6] Vet Adm Ann Arbor Healthcare Syst, Neurol Serv, Ann Arbor, MI 48105 USA
[7] Vet Adm Ann Arbor Healthcare Syst, GRECC, Ann Arbor, MI 48105 USA
[8] Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA
[9] Univ Med Ctr Rostock, Dept Psychosomat Med, D-18147 Rostock, Germany
[10] Univ Seville, Hosp Univ Virgen Rocio, Serv Neurol & Neurofisiol Clin, Unidad Trastornos Movimiento,CSIC,Inst Biomed Sevi, Seville 41013, Spain
[11] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid 28031, Spain
[12] Deutsch Zentrum Neurodegenerat Erkrankungen DZNE, Gehlsheimer Str 20, D-18147 Rostock, Germany
[13] Hosp Univ Virgen Rocio, Inst Biomed Sevilla, Unidad Trastornos Movimiento, Avda Manuel Siurot S-N, Seville 41013, Spain
关键词
basal forebrain; Parkinson's disease; MRI; positron emission tomography; acetylcholinesterase; cholinergic deficit; BASAL FOREBRAIN ATROPHY; ALZHEIMERS-DISEASE; NUCLEUS BASALIS; LEWY BODIES; IMPAIRMENT; DEMENTIA; DENERVATION; DEFICITS; MEMORY;
D O I
10.1093/brain/awad226
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Cognitive decline in Parkinson's disease is related to cholinergic system degeneration, which can be assessed in vivo using structural MRI markers of basal forebrain volume and PET measures of cortical cholinergic activity. In the present study we aimed to examine the interrelation between basal forebrain degeneration and PET-measured depletion of cortical acetylcholinesterase activity as well as their relative contribution to cognitive impairment in Parkinson's disease.This cross-sectional study included 143 Parkinson's disease participants without dementia and 52 healthy control participants who underwent structural MRI, PET scanning with 11C-methyl-4-piperidinyl propionate (PMP) as a measure of cortical acetylcholinesterase activity, and a detailed cognitive assessment. Based on the fifth percentile of the overall cortical PMP PET signal from the control group, people with Parkinson's disease were subdivided into a normo-cholinergic (n = 94) and a hypo-cholinergic group (n = 49). Volumes of functionally defined posterior and anterior basal forebrain subregions were extracted using an established automated MRI volumetry approach based on a stereotactic atlas of cholinergic basal forebrain nuclei. We used Bayesian t-tests to compare basal forebrain volumes between controls, and normo- and hypo-cholinergic Parkinson's participants after covarying out age, sex and years of education. Associations between the two cholinergic imaging measures were assessed across all people with Parkinson's disease using Bayesian correlations and their respective relations with performance in different cognitive domains were assessed with Bayesian ANCOVAs. As a specificity analysis, hippocampal volume was added to the analysis.We found evidence for a reduction of posterior basal forebrain volume in the hypo-cholinergic compared to both normo-cholinergic Parkinson's disease [Bayes factor against the null model (BF10) = 8.2] and control participants (BF10 = 6.0), while for the anterior basal forebrain the evidence was inconclusive (BF10 < 3). In continuous association analyses, posterior basal forebrain volume was significantly associated with cortical PMP PET signal in a temporo-posterior distribution. The combined models for the prediction of cognitive scores showed that both cholinergic markers (posterior basal forebrain volume and cortical PMP PET signal) were independently related to multi-domain cognitive deficits, and were more important predictors for all cognitive scores, including memory scores, than hippocampal volume.We conclude that degeneration of the posterior basal forebrain in Parkinson's disease is accompanied by functional cortical changes in acetylcholinesterase activity and that both PET and MRI cholinergic imaging markers are independently associated with multi-domain cognitive deficits in Parkinson's disease without dementia. Comparatively, hippocampal atrophy only seems to have minimal involvement in the development of early cognitive impairment in Parkinson's disease.
引用
收藏
页码:4964 / 4973
页数:10
相关论文
共 50 条
  • [21] Progression of regional cortical cholinergic denervation in Parkinson's disease
    Bohnen, Nicolaas, I
    Roytman, Stiven
    Kanel, Prabesh
    Muller, Martijn L. T. M.
    Scott, Peter J. H.
    Frey, Kirk A.
    Albin, Roger L.
    Koeppe, Robert A.
    BRAIN COMMUNICATIONS, 2022, 4 (06)
  • [22] Neurodegeneration Across Stages of Cognitive Decline in Parkinson Disease
    Weintraub, Daniel
    Doshi, Jimit
    Koka, Deepthi
    Davatzikos, Christos
    Siderowf, Andrew D.
    Duda, John E.
    Wolk, David A.
    Moberg, Paul J.
    Xie, Sharon X.
    Clark, Christopher M.
    ARCHIVES OF NEUROLOGY, 2011, 68 (12) : 1562 - 1568
  • [23] A task-specific cognitive domain decline is correlated with plasma and neuroimaging markers in patients with Parkinson's disease
    Li, Cheng-Hsuan
    Chen, Ta-Fu
    Peng, Pei-Ling
    Lin, Chin-Hsien
    JOURNAL OF NEUROLOGY, 2022, 269 (12) : 6530 - 6543
  • [24] Mapping Cholinergic Synaptic Loss in Parkinson's Disease: An [18F]FEOBV PET Case-Control Study
    Horsager, Jacob
    Okkels, Niels
    Hansen, Allan K.
    Damholdt, Malene F.
    Andersen, Katrine H.
    Fedorova, Tatyana D.
    Munk, Ole Lajord
    Danielsen, Erik H.
    Pavese, Nicola
    Brooks, David J.
    Borghammer, Per
    JOURNAL OF PARKINSONS DISEASE, 2022, 12 (08) : 2493 - 2506
  • [25] What predicts cognitive decline in de novo Parkinson's disease?
    Arnaldi, Dario
    Campus, Claudio
    Ferrara, Michela
    Fama, Francesco
    Picco, Agnese
    De Carli, Fabrizio
    Accardo, Jennifer
    Brugnolo, Andrea
    Sambuceti, Gianmario
    Morbelli, Silvia
    Nobili, Flavio
    NEUROBIOLOGY OF AGING, 2012, 33 (06) : 1127.e11 - 1127.e20
  • [26] The Interaction Between Neuroinflammation and β-Amyloid in Cognitive Decline in Parkinson's Disease
    Ghadery, Christine
    Koshimori, Yuko
    Christopher, Leigh
    Kim, Jinhee
    Rusjan, Pablo
    Lang, Anthony E.
    Houle, Sylvain
    Strafella, Antonio P.
    MOLECULAR NEUROBIOLOGY, 2020, 57 (01) : 492 - 501
  • [27] Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson's disease
    Kandiah, Nagaendran
    Zhang, Angeline
    Cenina, Alvin Rae
    Au, Wing Lok
    Nadkarni, Nivedita
    Tan, Louis Cs
    PARKINSONISM & RELATED DISORDERS, 2014, 20 (11) : 1145 - 1148
  • [28] Quantitative EEG and Cognitive Decline in Parkinson's Disease
    Cozac, Vitalii V.
    Gschwandtner, Ute
    Hatz, Florian
    Hardmeier, Martin
    Ruegg, Stephan
    Fuhr, Peter
    PARKINSONS DISEASE, 2016, 2016
  • [29] Cognitive decline in Parkinson disease
    Aarsland, Dag
    Creese, Byron
    Politis, Marios
    Chaudhuri, K. Ray
    Ffytche, Dominic H.
    Weintraub, Daniel
    Ballard, Clive
    NATURE REVIEWS NEUROLOGY, 2017, 13 (04) : 217 - 231
  • [30] Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia
    N. I. Bohnen
    D. I. Kaufer
    R. Hendrickson
    L. S. Ivanco
    B. J. Lopresti
    G. M. Constantine
    Ch. A. Mathis
    J. G. Davis
    R. Y. Moore
    S. T. DeKosky
    Journal of Neurology, 2006, 253 : 242 - 247